Delivery Order SPE2DB25D3020-SPE2DB25FWFYY

Award Date 2/14/25
Potential Completion Date 2/18/25
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $8,269.83 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract provides BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of June 28, 2024 and was awarded on June 27, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
This is a $4,997.70 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product, with a period of performance through April 30, 2024. This contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a $7,447.05 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of January 8, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This is a $126,594.86 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of September 22, 2023. Amerisourcebergen is a for-profit organization and a key vendor for federal healthcare programs, particularly within military and...
This is a $80,351.72 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML medication. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support...
This is a $17,280.22 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the provision of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used in the treatment of diabetes. The contract has a completion date of May 6, 2024 and was awarded on May 4, 2022. No set-aside designation was used for this contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This is a $3,052.30 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a prescription medication, with a performance period ending on October 13, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of...
This is a $10,220.85 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the provision of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML medical supplies. The award does not have a set-aside designation, indicating open competition. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order for $15,369.06 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide BYDUREON BCISE 2 MG AUTOINJECT 0.85ML medication. This delivery order is part of an indefinite delivery contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver pharmaceutical products and medical supplies to support military treatment programs worldwide. The...
This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,304.61, is for the delivery of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a type of medication. The contract is a firm fixed price contract with a period of performance ending on March 4, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that...
  • SPE2DB25D3020
    Indefinite Delivery Contract
  • SPE2DB25D3020-SPE2DB25FWFYY
    Delivery Order

This is a $2,199.76 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is to provide BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used for diabetes management. The contract has a period of performance through February 18, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, acting as a primary vehicle to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 11:58 AM